Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.58 |
| ▸ | KDR | P35968 | 6/20 | 0.50 |
| ▸ | AURKA | O14965 | 4/20 | 0.50 |
| ▸ | MET | P08581 | 4/20 | 0.50 |
| ▸ | TEK | Q02763 | 4/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 2/20 | 0.45 |
| ▸ | KLK1 | P06870 | 2/20 | 0.45 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7107874 | 0.99 | MTNR1A (0.56) | MTNR1AKDRAURKAMETTEK | |
| SCHEMBL8661902 | 0.82 | MTNR1A (0.78) | MTNR1AKDRAURKAMETTEK | |
| SCHEMBL31613069 | 0.82 | KDR (0.67) | MTNR1AKDRAURKAMETTEK | |
| SCHEMBL15121479 | 0.81 | PLAU (0.52) | PLGKLK1 | |
| SCHEMBL3100592 | 0.80 | MMP3 (0.62) | POLB | |
| SCHEMBL30071626 | 0.80 | MMP3 (0.62) | POLB | |
| SCHEMBL7108784 | 0.80 | MAOB (0.46) | KDRAURKBPOLBLCK | |
| SCHEMBL2237855 | 0.79 | MTNR1A (0.56) | MTNR1AKDRAURKAMETTEK | |
| Hydrochloric Acid SCHEMBL7110749 | 0.78 | MMP3 (0.61) | POLB | |
| Guanidine SCHEMBL27689978 | 0.78 | MMP3 (0.61) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6600072-B2 | Cardiovascular disorders; antiischemic agents; antiarrhythmia agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-29 | — | — | US | claimed |
| US-20030013760-A1 | Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | BRENDEL JOACHIM (DE) | 2003-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013760-A1 | Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | TNNI3, TNNT2, SCN1B | MTNR1A 306/4885KDR 3092/4885AURKA 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.